Top

World Journal of Urology

Published in:

Open Access 01-12-2018 | Topic Paper

Imaging for the diagnosis and response assessment of renal tumours

Authors: Sabrina H. Rossi, Davide Prezzi, Christian Kelly-Morland, Vicky Goh

Published in: World Journal of Urology | Issue 12/2018

Abstract

Purpose

Imaging plays a key role throughout the renal cell carcinoma (RCC) patient pathway, from diagnosis and staging of the disease, to the assessment of response to therapy. This review aims to summarise current knowledge with regard to imaging in the RCC patient pathway, highlighting recent advances and challenges.

Methods

A literature review was performed using Medline. Particular focus was paid to RCC imaging in the diagnosis, staging and response assessment following therapy.

Results

Characterisation of small renal masses (SRM) remains a diagnostic conundrum. Contrast-enhanced ultrasound (CEUS) has been increasingly applied in this field, as have emerging technologies such as multiparametric MRI, radiomics and molecular imaging with ^99mtechnetium-sestamibi single photon emission computed tomography/CT. CT remains the first-line modality for staging of locoregional and suspected metastatic disease. Although the staging accuracy of CT is good, limitations in determining nodal status persist. Response assessment following ablative therapies remains challenging, as reduction in tumour size may not occur. The pattern of enhancement on CT may be a more reliable indicator of treatment success. CEUS may also have a role in monitoring response following ablation. Response assessments following anti-angiogenic and immunotherapies in advanced RCC is an evolving field, with a number of alternative response criteria being proposed. Tumour response patterns may vary between different immunotherapy agents and tumour types; thus, future response criteria modifications may be inevitable.

Conclusion

The diagnosis and characterisation of SRM and response assessment following targeted therapy for advanced RCC are key challenges which warrant further research.

Znaor A, Laversanne M, Bray F (2017) Less overdiagnosis of kidney cancer? An age-period-cohort analysis of incidence trends in 16 populations worldwide. Int J Cancer 141(5):925–932. https://doi.org/10.1002/ijc.30799. Accessed 1 Mar 2018CrossRefPubMed

UK CR Kidney cancer incidence statistics. http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/kidney-cancer/incidence. Accessed 1 Mar 2018

Rossi SH, Klatte T, Usher-Smith J, Stewart GD (2018) Epidemiology and screening for renal cancer. World J Urol. https://doi.org/10.1007/s00345-018-2286-7 CrossRefPubMedPubMedCentral

Heilbrun ME, Yu J, Smith KJ, Dechet CB, Zagoria RJ, Roberts MS (2012) The cost-effectiveness of immediate treatment, percutaneous biopsy and active surveillance for the diagnosis of the small solid renal mass: evidence from a Markov model. J Urol 187(1):39–43. https://doi.org/10.1016/j.juro.2011.09.055 CrossRefPubMed

Ljungberg B, Bensalah K, Canfield S, Dabestani S, Hofmann F, Hora M, Kuczyk MA, Lam T, Marconi L, Merseburger AS, Mulders P, Powles T, Staehler M, Volpe A, Bex A (2015) EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol 67(5):913–924. https://doi.org/10.1016/j.eururo.2015.01.005 CrossRefPubMed

Krokidis ME, Orsi F, Katsanos K, Helmberger T, Adam A (2017) CIRSE guidelines on percutaneous ablation of small renal cell carcinoma. Cardiovasc Intervent Radiol 40(2):177–191. https://doi.org/10.1007/s00270-016-1531-y CrossRefPubMed

Campbell S, Uzzo RG, Allaf ME, Bass EB, Cadeddu JA, Chang A, Clark PE, Davis BJ, Derweesh IH, Giambarresi L, Gervais DA, Hu SL, Lane BR, Leibovich BC, Pierorazio PM (2017) Renal mass and localized renal cancer: AUA guideline. J Urol 198(3):520–529. https://doi.org/10.1016/j.juro.2017.04.100 CrossRefPubMed

Escudier B, Porta C, Schmidinger M, Rioux-Leclercq N, Bex A, Khoo V, Gruenvald V, Horwich A, Committee EG (2016) Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 27(suppl 5):v58–v68. https://doi.org/10.1093/annonc/mdw328 CrossRefPubMed

Davis R, Jones JS, Barocas DA, Castle EP, Lang EK, Leveillee RJ, Messing EM, Miller SD, Peterson AC, Turk TM, Weitzel W, American Urological A (2012) Diagnosis, evaluation and follow-up of asymptomatic microhematuria (AMH) in adults: AUA guideline. J Urol 188(6 Suppl):2473–2481. https://doi.org/10.1016/j.juro.2012.09.078 CrossRefPubMed

10.

Kassouf W, Aprikian A, Black P, Kulkarni G, Izawa J, Eapen L, Fairey A, So A, North S, Rendon R, Sridhar SS, Alam T, Brimo F, Blais N, Booth C, Chin J, Chung P, Drachenberg D, Fradet Y, Jewett M, Moore R, Morash C, Shayegan B, Gotto G, Fleshner N, Saad F, Siemens DR (2016) Recommendations for the improvement of bladder cancer quality of care in Canada: a consensus document reviewed and endorsed by Bladder Cancer Canada (BCC), Canadian Urologic Oncology Group (CUOG), and Canadian Urological Association (CUA). Can Urol Assoc J 10(1–2):E46–80. https://doi.org/10.5489/cuaj.3583 CrossRefPubMedPubMedCentral

11.

Shen LRRS, Beland MD et al (2014) American College of Radiologists Appropriateness Criteria: Hematuria 2014. https://acsearch.acr.org/docs/69490/Narrative. Accessed March 2018

12.

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228–247. https://doi.org/10.1016/j.ejca.2008.10.026 CrossRefPubMed

13.

Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR, Chen LL, Podoloff DA, Benjamin RS (2007) Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 25(13):1753–1759. https://doi.org/10.1200/JCO.2006.07.3049 CrossRefPubMed

14.

Nathan PD, Vinayan A, Stott D, Juttla J, Goh V (2010) CT response assessment combining reduction in both size and arterial phase density correlates with time to progression in metastatic renal cancer patients treated with targeted therapies. Cancer Biol Ther 9(1):15–19CrossRefPubMed

15.

Smith AD, Lieber ML, Shah SN (2010) Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT. AJR Am J Roentgenol 194(1):157–165. https://doi.org/10.2214/ajr.09.2941 CrossRefPubMed

16.

Smith AD, Shah SN, Rini BI, Lieber ML, Remer EM (2010) Morphology, Attenuation, Size, and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy. AJR Am J Roentgenol 194(6):1470–1478. https://doi.org/10.2214/ajr.09.3456 CrossRefPubMed

17.

Wolchok JD, Hoos A, O’Day S, Weber JS, Hamid O, Lebbe C, Maio M, Binder M, Bohnsack O, Nichol G, Humphrey R, Hodi FS (2009) Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 15(23):7412–7420. https://doi.org/10.1158/1078-0432.CCR-09-1624 CrossRefPubMed

18.

Hodi FS, Ballinger M, Lyons B, Soria JC, Nishino M, Tabernero J, Powles T, Smith D, Hoos A, McKenna C, Beyer U, Rhee I, Fine G, Winslow N, Chen DS, Wolchok JD (2018) Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): refining guidelines to assess the clinical benefit of cancer immunotherapy. J Clin Oncol. https://doi.org/10.1200/jco.2017.75.1644 CrossRefPubMed

19.

Ficarra V, Prayer-Galetti T, Novella G, Bratti E, Maffei N, Dal Bianco M, Artibani W, Pagano F (2003) Incidental detection beyond pathological factors as prognostic predictor of renal cell carcinoma. Eur Urol 43(6):663–669CrossRefPubMed

20.

Patard JJ, Rodriguez A, Rioux-Leclercq N, Guille F, Lobel B (2002) Prognostic significance of the mode of detection in renal tumours. BJU Int 90(4):358–363CrossRefPubMed

21.

Khadra MH, Pickard RS, Charlton M, Powell PH, Neal DE (2000) A prospective analysis of 1,930 patients with hematuria to evaluate current diagnostic practice. J Urol 163(2):524–527CrossRefPubMed

22.

Edwards TJ, Dickinson AJ, Natale S, Gosling J, McGrath JS (2006) A prospective analysis of the diagnostic yield resulting from the attendance of 4020 patients at a protocol-driven haematuria clinic. BJU Int 97(2):301–305; discussion 305. https://doi.org/10.1111/j.1464-410x.2006.05976.x

23.

Linder BJ, Bass EJ, Mostafid H, Boorjian SA (2018) Guideline of guidelines: asymptomatic microscopic haematuria. BJU Int 121(2):176–183. https://doi.org/10.1111/bju.14016 CrossRefPubMed

24.

Halpern JA, Chughtai B, Ghomrawi H (2017) Cost-effectiveness of common diagnostic approaches for evaluation of asymptomatic microscopic hematuria. JAMA Intern Med 177(6):800–807. https://doi.org/10.1001/jamainternmed.2017.0739 CrossRefPubMedPubMedCentral

25.

Amdahl J, Diaz J, Sharma A, Park J, Chandiwana D, Delea TE (2017) Cost-effectiveness of pazopanib versus sunitinib for metastatic renal cell carcinoma in the United Kingdom. PLoS ONE 12(6):e0175920. https://doi.org/10.1371/journal.pone.0175920 CrossRefPubMedPubMedCentral

26.

Warshauer DM, McCarthy SM, Street L, Bookbinder MJ, Glickman MG, Richter J, Hammers L, Taylor C, Rosenfield AT (1988) Detection of renal masses: sensitivities and specificities of excretory urography/linear tomography, US, and CT. Radiology 169(2):363–365. https://doi.org/10.1148/radiology.169.2.3051112 CrossRefPubMed

27.

O’Connor OJ, McSweeney SE, Maher MM (2008) Imaging of hematuria. Radiol Clin N Am 46(1):113–132, vii. https://doi.org/10.1016/j.rcl.2008.01.007

28.

Cowan NC (2012) CT urography for hematuria. Nat Rev Urol 9(4):218–226. https://doi.org/10.1038/nrurol.2012.32 CrossRefPubMed

29.

Gray Sears CL, Ward JF, Sears ST, Puckett MF, Kane CJ, Amling CL (2002) Prospective comparison of computerized tomography and excretory urography in the initial evaluation of asymptomatic microhematuria. J Urol 168(6):2457–2460. https://doi.org/10.1097/01.ju.0000036541.52816.98 CrossRefPubMed

30.

Silverman SG, Leyendecker JR, Amis ES Jr (2009) What is the current role of CT urography and MR urography in the evaluation of the urinary tract? Radiology 250(2):309–323. https://doi.org/10.1148/radiol.2502080534 CrossRefPubMed

31.

Rabjerg M, Mikkelsen MN, Walter S, Marcussen N (2014) Incidental renal neoplasms: is there a need for routine screening? A Danish single-center epidemiological study. APMIS 122(8):708–714. https://doi.org/10.1111/apm.12282 CrossRefPubMed

32.

Welch HG, Skinner JS, Schroeck FR, Zhou W, Black WC (2018) Regional variation of computed tomographic imaging in the United States and the risk of nephrectomy. JAMA Intern Med 178(2):221–227. https://doi.org/10.1001/jamainternmed.2017.7508 CrossRefPubMed

33.

O’Connor SD, Pickhardt PJ, Kim DH, Oliva MR, Silverman SG (2011) Incidental finding of renal masses at unenhanced CT: prevalence and analysis of features for guiding management. AJR Am J Roentgenol 197(1):139–145. https://doi.org/10.2214/ajr.10.5920 CrossRefPubMed

34.

Bosniak MA (1986) The current radiological approach to renal cysts. Radiology 158(1):1–10. https://doi.org/10.1148/radiology.158.1.3510019 CrossRefPubMed

35.

Sevcenco S, Spick C, Helbich TH, Heinz G, Shariat SF, Klingler HC, Rauchenwald M, Baltzer PA (2017) Malignancy rates and diagnostic performance of the Bosniak classification for the diagnosis of cystic renal lesions in computed tomography—a systematic review and meta-analysis. Eur Radiol 27(6):2239–2247. https://doi.org/10.1007/s00330-016-4631-9 CrossRefPubMed

36.

Birnbaum BA, Hindman N, Lee J, Babb JS (2007) Renal cyst pseudoenhancement: influence of multidetector CT reconstruction algorithm and scanner type in phantom model. Radiology 244(3):767–775. https://doi.org/10.1148/radiol.2443061537 CrossRefPubMed

37.

Schoots IG, Zaccai K, Hunink MG, Verhagen P (2017) Bosniak classification for complex renal cysts reevaluated: a systematic review. J Urol 198(1):12–21. https://doi.org/10.1016/j.juro.2016.09.160 CrossRefPubMed

38.

Pitra T, Pivovarcikova K, Tupy R, Alaghehbandan R, Barakova T, Travnicek I, Prochazkova K, Klatte T, Chlosta P, Hes O, Hora M (2018) Magnetic resonance imaging as an adjunct diagnostic tool in computed tomography defined Bosniak IIF-III renal cysts: a multicenter study. World J Urol. https://doi.org/10.1007/s00345-018-2176-z CrossRefPubMed

39.

Bosniak MA (2012) The Bosniak renal cyst classification: 25 years later. Radiology 262(3):781–785. https://doi.org/10.1148/radiol.11111595 CrossRefPubMed

40.

Ascenti G, Mazziotti S, Zimbaro G, Settineri N, Magno C, Melloni D, Caruso R, Scribano E (2007) Complex cystic renal masses: characterization with contrast-enhanced US. Radiology 243(1):158–165. https://doi.org/10.1148/radiol.2431051924 CrossRefPubMed

41.

Quaia E, Bertolotto M, Cioffi V, Rossi A, Baratella E, Pizzolato R, Cov MA (2008) Comparison of contrast-enhanced sonography with unenhanced sonography and contrast-enhanced CT in the diagnosis of malignancy in complex cystic renal masses. AJR Am J Roentgenol 191(4):1239–1249. https://doi.org/10.2214/AJR.07.3546 CrossRefPubMed

42.

Defortescu G, Cornu JN, Bejar S, Giwerc A, Gobet F, Werquin C, Pfister C, Nouhaud FX (2017) Diagnostic performance of contrast-enhanced ultrasonography and magnetic resonance imaging for the assessment of complex renal cysts: a prospective study. Int J Urol 24(3):184–189. https://doi.org/10.1111/iju.13289 CrossRefPubMed

43.

Johnson DC, Vukina J, Smith AB, Meyer AM, Wheeler SB, Kuo TM, Tan HJ, Woods ME, Raynor MC, Wallen EM, Pruthi RS, Nielsen ME (2015) Preoperatively misclassified, surgically removed benign renal masses: a systematic review of surgical series and United States population level burden estimate. J Urol 193(1):30–35. https://doi.org/10.1016/j.juro.2014.07.102 CrossRefPubMed

44.

Schlomer B, Figenshau RS, Yan Y, Venkatesh R, Bhayani SB (2006) Pathological features of renal neoplasms classified by size and symptomatology. J Urol 176(4 Pt 1):1317–1320; discussion 1320. https://doi.org/10.1016/j.juro.2006.06.005

45.

Akdogan B, Gudeloglu A, Inci K, Gunay LM, Koni A, Ozen H (2012) Prevalence and predictors of benign lesions in renal masses smaller than 7 cm presumed to be renal cell carcinoma. Clin Genitourin Cancer 10(2):121–125. https://doi.org/10.1016/j.clgc.2012.01.005 CrossRefPubMed

46.

Golan S, Eggener S, Subotic S, Barret E, Cormio L, Naito S, Tefekli A, Pilar Laguna Pes M (2016) Prediction of renal mass aggressiveness using clinical and radiographic features: a global, multicentre prospective study. BJU Int 117(6):914–922. https://doi.org/10.1111/bju.13331 CrossRefPubMed

47.

Bauman TM, Potretzke AM, Wright AJ, Knight BA, Vetter JM, Figenshau RS (2017) Partial nephrectomy for presumed renal-cell carcinoma: incidence, predictors, and perioperative outcomes of benign lesions. J Endourol 31(4):412–417. https://doi.org/10.1089/end.2016.0667 CrossRefPubMed

48.

Secin FP, Castillo OA, Rozanec JJ, Featherston M, Holst P, Milfont JC, Garcia Marchinena P, Jurado Navarro A, Autran A, Rovegno AR, Faba OR, Palou J, Teixeira Dubeux V, Nunez Bragayrac L, Sotelo R, Zequi S, Guimaraes GC, Alvarez-Maestro M, Martinez-Pineiro L, Villoldo G, Villaronga A, Abreu Clavijo D, Decia R, Frota R, Vidal-Mora I, Finkelstein D, Monzo Gardiner JI, Schatloff O, Hernandez-Porras A, Santaella-Torres F, Quesada ET, Sanchez-Salas R, Davila H, Mavric HV (2017) American Confederation of Urology (CAU) experience in minimally invasive partial nephrectomy. World J Urol 35(1):57–65. https://doi.org/10.1007/s00345-016-1837-z CrossRefPubMed

49.

Millet I, Doyon FC, Hoa D, Thuret R, Merigeaud S, Serre I, Taourel P (2011) Characterization of small solid renal lesions: can benign and malignant tumors be differentiated with CT? AJR Am J Roentgenol 197(4):887–896. https://doi.org/10.2214/AJR.10.6276 CrossRefPubMed

50.

Kim JK, Park SY, Shon JH, Cho KS (2004) Angiomyolipoma with minimal fat: differentiation from renal cell carcinoma at biphasic helical CT. Radiology 230(3):677–684. https://doi.org/10.1148/radiol.2303030003 CrossRefPubMed

51.

Hafron J, Fogarty JD, Hoenig DM, Li M, Berkenblit R, Ghavamian R (2005) Imaging characteristics of minimal fat renal angiomyolipoma with histologic correlations. Urology 66(6):1155–1159. https://doi.org/10.1016/j.urology.2005.06.119 CrossRefPubMed

52.

Schieda N, Hodgdon T, El-Khodary M, Flood TA, McInnes MD (2014) Unenhanced CT for the diagnosis of minimal-fat renal angiomyolipoma. AJR Am J Roentgenol 203(6):1236–1241. https://doi.org/10.2214/AJR.14.12630 CrossRefPubMed

53.

Woo S, Suh CH, Cho JY, Kim SY, Kim SH (2017) Diagnostic performance of CT for diagnosis of fat-poor angiomyolipoma in patients with renal masses: a systematic review and meta-analysis. AJR Am J Roentgenol 209(5):W297–W307. https://doi.org/10.2214/AJR.17.18184 CrossRefPubMed

54.

Neves JB, Withington J, Fowler S, Patki P, Barod R, Mumtaz F, O’Brien T, Aitchison M, Bex A, Tran MGB, British Association of Urological Surgeons (2018) Contemporary surgical management of renal oncocytoma: a nation’s outcome. BJU Int. https://doi.org/10.1111/bju.14159 CrossRefPubMed

55.

Patel HD, Druskin SC, Rowe SP, Pierorazio PM, Gorin MA, Allaf ME (2017) Surgical histopathology for suspected oncocytoma on renal mass biopsy: a systematic review and meta-analysis. BJU Int 119(5):661–666. https://doi.org/10.1111/bju.13763 CrossRefPubMed

56.

Galia M, Albano D, Bruno A, Agrusa A, Romano G, Di Buono G, Agnello F, Salvaggio G, La Grutta L, Midiri M, Lagalla R (2017) Imaging features of solid renal masses. Br J Radiol 90(1077):20170077. https://doi.org/10.1259/bjr.20170077 CrossRefPubMedPubMedCentral

57.

Kim JI, Cho JY, Moon KC, Lee HJ, Kim SH (2009) Segmental enhancement inversion at biphasic multidetector CT: characteristic finding of small renal oncocytoma. Radiology 252(2):441–448. https://doi.org/10.1148/radiol.2522081180 CrossRefPubMed

58.

Cornelis F, Lasserre AS, Tourdias T, Deminiere C, Ferriere JM, Le Bras Y, Grenier N (2013) Combined late gadolinium-enhanced and double-echo chemical-shift MRI help to differentiate renal oncocytomas with high central T2 signal intensity from renal cell carcinomas. AJR Am J Roentgenol 200(4):830–838. https://doi.org/10.2214/AJR.12.9122 CrossRefPubMed

59.

Schieda N, McInnes MD, Cao L (2014) Diagnostic accuracy of segmental enhancement inversion for diagnosis of renal oncocytoma at biphasic contrast enhanced CT: systematic review. Eur Radiol 24(6):1421–1429. https://doi.org/10.1007/s00330-014-3147-4 CrossRefPubMed

60.

Young JR, Margolis D, Sauk S, Pantuck AJ, Sayre J, Raman SS (2013) Clear cell renal cell carcinoma: discrimination from other renal cell carcinoma subtypes and oncocytoma at multiphasic multidetector CT. Radiology 267(2):444–453. https://doi.org/10.1148/radiol.13112617 CrossRefPubMed

61.

Taouli B, Thakur RK, Mannelli L, Babb JS, Kim S, Hecht EM, Lee VS, Israel GM (2009) Renal lesions: characterization with diffusion-weighted imaging versus contrast-enhanced MR imaging. Radiology 251(2):398–407. https://doi.org/10.1148/radiol.2512080880 CrossRefPubMed

62.

Vargas HA, Chaim J, Lefkowitz RA, Lakhman Y, Zheng J, Moskowitz CS, Sohn MJ, Schwartz LH, Russo P, Akin O (2012) Renal cortical tumors: use of multiphasic contrast-enhanced MR imaging to differentiate benign and malignant histologic subtypes. Radiology 264(3):779–788. https://doi.org/10.1148/radiol.12110746 CrossRefPubMed

63.

Galmiche C, Bernhard JC, Yacoub M, Ravaud A, Grenier N, Cornelis F (2017) Is multiparametric MRI useful for differentiating oncocytomas from chromophobe renal cell carcinomas? AJR Am J Roentgenol 208(2):343–350. https://doi.org/10.2214/AJR.16.16832 CrossRefPubMed

64.

Perazella MA, Rodby RA (2007) Gadolinium use in patients with kidney disease: a cause for concern. Semin Dial 20(3):179–185. https://doi.org/10.1111/j.1525-139X.2007.00269.x CrossRefPubMed

65.

Wang C, Yu C, Yang F, Yang G (2014) Diagnostic accuracy of contrast-enhanced ultrasound for renal cell carcinoma: a meta-analysis. Tumour Biol 35(7):6343–6350. https://doi.org/10.1007/s13277-014-1815-2 CrossRefPubMed

66.

Tenant SC, Gutteridge CM (2016) The clinical use of contrast-enhanced ultrasound in the kidney. Ultrasound 24(2):94–103. https://doi.org/10.1177/1742271X15627185 CrossRefPubMedPubMedCentral

67.

Prezzi D, Neji R, Kelly-Morland C, Verma H, O’Brien T, Challacombe B, Fernando A, Chandra A, Sinkus R, Goh V (2018) Characterization of small renal tumors with magnetic resonance elastography: a feasibility study. Invest Radiol. https://doi.org/10.1097/RLI.0000000000000449 CrossRefPubMed

68.

Lambin P, Leijenaar RTH, Deist TM, Peerlings J, de Jong EEC, van Timmeren J, Sanduleanu S, Larue R, Even AJG, Jochems A, van Wijk Y, Woodruff H, van Soest J, Lustberg T, Roelofs E, van Elmpt W, Dekker A, Mottaghy FM, Wildberger JE, Walsh S (2017) Radiomics: the bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol 14(12):749–762. https://doi.org/10.1038/nrclinonc.2017.141 CrossRefPubMed

69.

Yu H, Scalera J, Khalid M, Touret AS, Bloch N, Li B, Qureshi MM, Soto JA, Anderson SW (2017) Texture analysis as a radiomic marker for differentiating renal tumors. Abdom Radiol. https://doi.org/10.1007/s00261-017-1144-1 CrossRef

70.

Gorin MA, Rowe SP, Baras AS, Solnes LB, Ball MW, Pierorazio PM, Pavlovich CP, Epstein JI, Javadi MS, Allaf ME (2016) Prospective evaluation of (99m)Tc-sestamibi SPECT/CT for the diagnosis of renal oncocytomas and hybrid oncocytic/chromophobe tumors. Eur Urol 69(3):413–416. https://doi.org/10.1016/j.eururo.2015.08.056 CrossRefPubMed

71.

Sheikhbahaei S, Jones CS, Porter KK, Rowe SP, Gorin MA, Baras AS, Pierorazio PM, Ball MW, Higuchi T, Johnson PT, Solnes LB, Epstein JI, Allaf ME, Javadi MS (2017) Defining the added value of 99mTc-MIBI SPECT/CT to conventional cross-sectional imaging in the characterization of enhancing solid renal masses. Clin Nucl Med 42(4):e188–e193. https://doi.org/10.1097/RLU.0000000000001534 CrossRefPubMed

72.

Jones KM, Solnes LB, Rowe SP, Gorin MA, Sheikhbahaei S, Fung G, Frey EC, Allaf ME, Du Y, Javadi MS (2018) Use of quantitative SPECT/CT reconstruction in (99m)Tc-sestamibi imaging of patients with renal masses. Ann Nucl Med 32(2):87–93. https://doi.org/10.1007/s12149-017-1222-z CrossRefPubMed

73.

Five-Year Relative Survival by Stage, Adults (Aged 15-99 Years), Former Anglia Cancer Network, 2002–2006 (2014) Cancer Research UK. http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/kidney-cancer/survival#heading-Three. Accessed 26 July 2016

74.

Johnson CD, Dunnick NR, Cohan RH, Illescas FF (1987) Renal adenocarcinoma: CT staging of 100 tumors. AJR Am J Roentgenol 148(1):59–63. https://doi.org/10.2214/ajr.148.1.59 CrossRefPubMed

75.

Nayak JG, Patel P, Saarela O, Liu Z, Kapoor A, Finelli A, Tanguay S, Rendon R, Moore R, Black PC, Lacombe L, Breau RH, Kawakami J, Drachenberg DE (2016) Pathological upstaging of clinical T1 to pathological T3a renal cell carcinoma: a multi-institutional analysis of short-term outcomes. Urology 94:154–160. https://doi.org/10.1016/j.urology.2016.03.029 CrossRefPubMed

76.

Studer UE, Scherz S, Scheidegger J, Kraft R, Sonntag R, Ackermann D, Zingg EJ (1990) Enlargement of regional lymph nodes in renal cell carcinoma is often not due to metastases. J Urol 144(2 Pt 1):243–245CrossRefPubMed

77.

Semelka RC, Shoenut JP, Magro CM, Kroeker MA, MacMahon R, Greenberg HM (1993) Renal cancer staging: comparison of contrast-enhanced CT and gadolinium-enhanced fat-suppressed spin-echo and gradient-echo MR imaging. J Magn Reson Imaging 3(4):597–602CrossRefPubMed

78.

Goldberg MA, Mayo-Smith WW, Papanicolaou N, Fischman AJ, Lee MJ (1997) FDG PET characterization of renal masses: preliminary experience. Clin Radiol 52(7):510–515CrossRefPubMed

79.

Ramdave S, Thomas GW, Berlangieri SU, Bolton DM, Davis I, Danguy HT, Macgregor D, Scott AM (2001) Clinical role of F-18 fluorodeoxyglucose positron emission tomography for detection and management of renal cell carcinoma. J Urol 166(3):825–830CrossRefPubMed

80.

Shvarts O, Lam JS, Kim HL, Han KR, Figlin R, Belldegrun A (2004) Eastern Cooperative Oncology Group performance status predicts bone metastasis in patients presenting with renal cell carcinoma: implication for preoperative bone scans. J Urol 172(3):867–870. https://doi.org/10.1097/01.ju.0000135803.91207.b0 CrossRefPubMed

81.

Koga S, Tsuda S, Nishikido M, Ogawa Y, Hayashi K, Hayashi T, Kanetake H (2001) The diagnostic value of bone scan in patients with renal cell carcinoma. J Urol 166(6):2126–2128CrossRefPubMed

82.

Wu HC, Yen RF, Shen YY, Kao CH, Lin CC, Lee CC (2002) Comparing whole body 18F-2-deoxyglucose positron emission tomography and technetium-99m methylene diphosphate bone scan to detect bone metastases in patients with renal cell carcinomas—a preliminary report. J Cancer Res Clin Oncol 128(9):503–506. https://doi.org/10.1007/s00432-002-0370-1 CrossRefPubMed

83.

Kawamoto S, Permpongkosol S, Bluemke DA, Fishman EK, Solomon SB (2007) Sequential changes after radiofrequency ablation and cryoablation of renal neoplasms: role of CT and MR imaging. Radiographics 27(2):343–355. https://doi.org/10.1148/rg.272065119 CrossRefPubMed

84.

Stein AJ, Mayes JM, Mouraviev V, Chen VH, Nelson RC, Polascik TJ (2008) Persistent contrast enhancement several months after laparoscopic cryoablation of the small renal mass may not indicate recurrent tumor. J Endourol 22(11):2433–2439. https://doi.org/10.1089/end.2008.0261 CrossRefPubMed

85.

Weight CJ, Kaouk JH, Hegarty NJ, Remer EM, O’Malley CM, Lane BR, Gill IS, Novick AC (2008) Correlation of radiographic imaging and histopathology following cryoablation and radio frequency ablation for renal tumors. J Urol 179(4):1277–1281; discussion 1281–1273. https://doi.org/10.1016/j.juro.2007.11.075

86.

Iannuccilli JD, Grand DJ, Dupuy DE, Mayo-Smith WW (2014) Percutaneous ablation for small renal masses-imaging follow-up. Semin Intervent Radiol 31(1):50–63. https://doi.org/10.1055/s-0033-1363843 CrossRefPubMedPubMedCentral

87.

Ganguli S, Brennan DD, Faintuch S, Rayan ME, Goldberg SN (2008) Immediate renal tumor involution after radiofrequency thermal ablation. J Vasc Interv Radiol 19(3):412–418. https://doi.org/10.1016/j.jvir.2007.10.024 CrossRefPubMed

88.

Gill IS, Remer EM, Hasan WA, Strzempkowski B, Spaliviero M, Steinberg AP, Kaouk JH, Desai MM, Novick AC (2005) Renal cryoablation: outcome at 3 years. J Urol 173(6):1903–1907. https://doi.org/10.1097/01.ju.0000158154.28845.c9 CrossRefPubMed

89.

Goldberg SN, Grassi CJ, Cardella JF, Charboneau JW, Dodd GD, 3rd, Dupuy DE, Gervais D, Gillams AR, Kane RA, Lee FT, Jr., Livraghi T, McGahan J, Phillips DA, Rhim H, Silverman SG, Society of Interventional Radiology Technology Assessment C, International Working Group on Image-Guided Tumor A (2005) Image-guided tumor ablation: standardization of terminology and reporting criteria. Radiology 235(3):728–739. https://doi.org/10.1148/radiol.2353042205 CrossRef

90.

Ahmed M, Solbiati L, Brace CL, Breen DJ, Callstrom MR, Charboneau JW, Chen MH, Choi BI, de Baere T, Dodd GD 3rd, Dupuy DE, Gervais DA, Gianfelice D, Gillams AR, Lee FT Jr, Leen E, Lencioni R, Littrup PJ, Livraghi T, Lu DS, McGahan JP, Meloni MF, Nikolic B, Pereira PL, Liang P, Rhim H, Rose SC, Salem R, Sofocleous CT, Solomon SB, Soulen MC, Tanaka M, Vogl TJ, Wood BJ, Goldberg SN, International Working Group on Image-guided Tumor A, Interventional Oncology Sans Frontieres Expert P, Technology Assessment Committee of the Society of Interventional R, Standard of Practice Committee of the C, Interventional Radiological Society of E (2014) Image-guided tumor ablation: standardization of terminology and reporting criteria—a 10-year update. Radiology 273(1):241–260. https://doi.org/10.1148/radiol.14132958 CrossRefPubMed

91.

Donat SM, Diaz M, Bishoff JT, Coleman JA, Dahm P, Derweesh IH, Herrell SD 3rd, Hilton S, Jonasch E, Lin DW, Reuter VE, Chang SS (2013) Follow-up for clinically localized renal neoplasms: AUA guideline. J Urol 190(2):407–416. https://doi.org/10.1016/j.juro.2013.04.121 CrossRefPubMed

92.

Matin SF, Ahrar K, Cadeddu JA, Gervais DA, McGovern FJ, Zagoria RJ, Uzzo RG, Haaga J, Resnick MI, Kaouk J, Gill IS (2006) Residual and recurrent disease following renal energy ablative therapy: a multi-institutional study. J Urol 176(5):1973–1977. https://doi.org/10.1016/j.juro.2006.07.016 CrossRefPubMed

93.

Klatte T, Kroeger N, Zimmermann U, Burchardt M, Belldegrun AS, Pantuck AJ (2014) The contemporary role of ablative treatment approaches in the management of renal cell carcinoma (RCC): focus on radiofrequency ablation (RFA), high-intensity focused ultrasound (HIFU), and cryoablation. World J Urol 32(3):597–605. https://doi.org/10.1007/s00345-014-1284-7 CrossRefPubMed

94.

Bex A, Fournier L, Lassau N, Mulders P, Nathan P, Oyen WJ, Powles T (2014) Assessing the response to targeted therapies in renal cell carcinoma: technical insights and practical considerations. Eur Urol 65(4):766–777. https://doi.org/10.1016/j.eururo.2013.11.031 CrossRefPubMed

95.

Sirous R, Henegan JC, Zhang X, Howard CM, Souza F, Smith AD (2016) Metastatic renal cell carcinoma imaging evaluation in the era of anti-angiogenic therapies. Abdom Radiol 41(6):1086–1099. https://doi.org/10.1007/s00261-016-0742-7 CrossRef

96.

Goh V, Ganeshan B, Nathan P, Juttla JK, Vinayan A, Miles KA (2011) Assessment of response to tyrosine kinase inhibitors in metastatic renal cell cancer: CT texture as a predictive biomarker. Radiology 261(1):165–171. https://doi.org/10.1148/radiol.11110264 CrossRefPubMed

97.

Hudson JM, Bailey C, Atri M, Stanisz G, Milot L, Williams R, Kiss A, Burns PN, Bjarnason GA (2018) The prognostic and predictive value of vascular response parameters measured by dynamic contrast-enhanced-CT, -MRI and -US in patients with metastatic renal cell carcinoma receiving sunitinib. Eur Radiol. https://doi.org/10.1007/s00330-017-5220-2 CrossRefPubMed

98.

Crusz SM, Tang YZ, Sarker SJ, Prevoo W, Kiyani I, Beltran L, Peters J, Sahdev A, Bex A, Powles T, Gerlinger M (2016) Heterogeneous response and progression patterns reveal phenotypic heterogeneity of tyrosine kinase inhibitor response in metastatic renal cell carcinoma. BMC Med 14(1):185. https://doi.org/10.1186/s12916-016-0729-9 CrossRefPubMedPubMedCentral

99.

Nishino M, Jagannathan JP, Krajewski KM, O’Regan K, Hatabu H, Shapiro G, Ramaiya NH (2012) Personalized tumor response assessment in the era of molecular medicine: cancer-specific and therapy-specific response criteria to complement pitfalls of RECIST. AJR Am J Roentgenol 198(4):737–745. https://doi.org/10.2214/ajr.11.7483 CrossRefPubMedPubMedCentral

100.

Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, Lin NU, Litiere S, Dancey J, Chen A, Hodi FS, Therasse P, Hoekstra OS, Shankar LK, Wolchok JD, Ballinger M, Caramella C, de Vries EG, RECIST Working Group (2017) iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol 18(3):e143–e152. https://doi.org/10.1016/S1470-2045(17)30074-8 CrossRefPubMedPubMedCentral

101.

Jamis-Dow CA, Choyke PL, Jennings SB, Linehan WM, Thakore KN, Walther MM (1996) Small (< or = 3-cm) renal masses: detection with CT versus US and pathologic correlation. Radiology 198(3):785–788. https://doi.org/10.1148/radiology.198.3.8628872 CrossRefPubMed

Title: Imaging for the diagnosis and response assessment of renal tumours
Authors: Sabrina H. Rossi
Davide Prezzi
Christian Kelly-Morland
Vicky Goh
Publication date: 01-12-2018
Publisher: Springer Berlin Heidelberg
Published in: World Journal of Urology / Issue 12/2018
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-018-2342-3

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Imaging for the diagnosis and response assessment of renal tumours

Abstract

Purpose

Methods

Results

Conclusion

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 12/2018

SIU-NewsLetter - December 2018

Renal cell carcinoma: standards and controversies

Muscle-invasive bladder cancer organ-preserving therapy: systematic review and meta-analysis

Advanced non-contrasted computed tomography post-processing by CT-Calculometry (CT-CM) outperforms established predictors for the outcome of shock wave lithotripsy

Letter to the editor: considering the effects of deep neuromuscular blockade on endoscopic surgical conditions during transurethral resection of a bladder tumor (TURB)

Answer to comment on manuscript “Prognostic significance of Fuhrman grade and age for cancer-specific and overall survival in patients with papillary renal cell carcinoma: results of an international multi-institutional study on 2189 patients”